WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas Canadian Stock Exchange:WBIO.CN
VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) – WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company“Or”WPDA clinical-stage pharmaceutical company, is pleased to announce that it will be attending the 10th Annual Congress of the Polish Association of Pediatric Oncology and Hematology to be held May 6-8, 2021.
During the conference, WPD will present key assumptions of the WPD-201P Clinical Trial Protocol, scheduled to start in Q2 2021, as part of the research project: “New Approach to Glioblastoma Treatment Addressing Critical Unmet medical need “granted by National Research and Development Center (“NRDC”) And co-financed by the European Union under the Smart Growth Operational Program 2014-2020.
Berubicin is a second generation anthracycline candidate for the treatment of a number of central nervous system cancers, including Glioblastoma Multiforme (GBM) and Malignant Gliomas. Anthracyclines are designed to use natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by disrupting the action of topoisomerase II, a crucial enzyme that enables cell proliferation. Berubicin was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at the University of Texas MD Anderson Cancer Center, and showed positive responses, including one sustained complete response in a Phase 1 human clinical trial previously conducted by Reata Pharmaceuticals, Inc.
Mariusz Olejniczak, CEO of WPD noted, “We are very excited about the opportunity to share our Phase I pediatric clinical trial protocol with members of the Pediatric Oncology Association. This will be a great opportunity to promote our project and create the opportunity for future collaboration. “
WPD also announces that it has engaged Strikepoint Media LLC. (“Battle point”), To provide digital marketing and brand awareness support. The company has agreed to pay Strikepoint $ 50,000 for a three-month digital media term beginning April 26, 2021. Strikepoint will not receive securities from the company as compensation for their services.
About WPD Pharmaceuticals
WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of drugs with biological compounds and small molecules. WPD has licensed 10 new drug candidates in certain countries, 4 of which are in the clinical development phase. These drug candidates have been investigated at medical institutions and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.
WPD has licensing agreements with Wake Forest University Health Sciences and sub-licensing agreements with Moleculin Biotech, Inc., respectively. and CNS Pharmaceuticals, Inc., each of which grants WPD an exclusive, royalty-bearing sub-license for certain technologies from the licensor. Such agreements give WPD, among other things, certain research, development, manufacturing and sales rights. The CNS Pharmaceuticals and Moleculin Biotech sub-license area covers 30 countries in Europe and Asia, including Russia, for most compounds.
On behalf of the Board
CEO, WDP Pharmaceuticals
Arrowhead Business and Investment Decisions, LLC
42 Broadway, 17th floor
New York, NY 10004
Office: +1 212 619-6889
Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada assumes responsibility for the sufficiency or accuracy of this communication.
This press release contains forward-looking statements. Forward-looking statements are statements that consider activities, events or developments that the Company expects will or may occur in the future. Forward-looking statements in this press release include that we have access to the rest of our NCRD grants and that WPD’s drugs can be developed into new treatments for cancer. These forward-looking statements reflect the company’s current expectations based on information currently available to management and are subject to a number of risks and uncertainties that could cause results to differ materially from expected results. Factors that may prevent the forward-looking statement from being realized are that competitors or others may successfully challenge a granted patent and that the patent may be invalidated; that we cannot raise enough money for our research; that we may not meet the requirements to receive the awarded scholarships; that our drugs do not provide positive treatment, or if they do, the side effects are harmful; competitors can develop better or cheaper medicines; and we may not be able to get regulatory approval for drugs we develop. Readers should refer to the risk disclosure included from time to time in the Company’s records on SEDAR, available at www.sedar.com. While the company believes that the assumptions inherent in these forward-looking statements are reasonable, they are not guarantees of future performance and, therefore, should not be relied upon and cannot be guaranteed that any of the assumptions will prove to be correct. to be. Finally, these forward-looking statements are made as of the date of this press release and the company assumes no obligation to update them, except as required by applicable law.